BIBLIOGRAPHY

Cavazzana-Calvo, M., et al., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 2000. 288(5466): p. 669-72.

Hacein-Bey-Abina, S., et al., Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New England Journal of Medicine, 2002. 346(16): p. 1185-1193.

Hacein-Bey-Abina, S., et al., A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003. 348(3): p. 255-6.

Suzuki, T., et al., New genes involved in cancer identified by retroviral tagging. Nat Genet, 2002. 32(1): p. 166-74.

Li, Z., et al., Murine leukemia induced by retroviral gene marking. Science, 2002. 296: p. 497.

Baum, C., et al., Side effects of retroviral gene transfer into hematopoietic stem cells. Blood, 2003.

Otsu, M., K. Sugamura, and F. Candotti, Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice. Blood, 2001. 97(6): p. 1618-24.

Soudais, C., et al., Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer. Blood, 2000. 95(10): p. 3071-7.

Lo, M., et al., Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood, 1999. 94(9): p. 3027-36.

Whitwam, T., et al., Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes. Blood, 1998. 92(5): p. 1565-75.

Fehniger, T.A., et al., Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis, 2001. 27(1): p. 223-30.

Renauld, J.C., et al., Thymic lymphomas in interleukin 9 transgenic mice. Oncogene, 1994. 9(5): p. 1327-32.

Blaese, R. M., K. W. Culver, A. D. Miller, C. S. Carter, T. Fleisher, M. Clerici, G. Shearer, L. Chang, Y. Chiang, P. Tolstoshev, J. J. Greenblatt, S. A. Rosenberg, H. Klein, M. Berger, C. A. Mullen, W. J. Ramsey, L. Muul, R. A. Morgan, and W. F. Anderson. 1995. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270:475-480.

Bordignon, C., L. D. Notarangelo, N. Nobili, G. Ferrari, G. Casorati, P. Panina, N. Mazzolari, D. Maggioni, C. Rossi, P. Servida, A. G. Ugazio, and F. Mavilio. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-475.

Buckley, R. H., S. E. Schiff, R. I. Schiff, L. Markert, L. W. Williams, J. L. Roberts, L. A. Myers, and F. E. Ward. 1999. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. The New England Journal of Medicine 340:508-516.

Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, F. Gross, E. Yvon, P. Nusbaum, F. Selz, C. Hue, S. Certain, J. L. Casanova, P. Bousso, F. L. Deist, and A. Fischer. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72.

Fischer, A. 2000. Severe combined immunodeficiencies (SCID). Clinical Experimental Immunology 122:143-149.

Fischer, A., S. Hacein-Bey, and M. Cavazzano-Calvo. 2002. Gene therapy of severe combined immunodeficiencies. Nature Reviews: Immunology 2:615-621.

Hacein-Bey-Abina, S., F. Le Deist, F. Carlier, C. Bouneaud, C. Hue, J. De Villartay, A. J. Thrasher, N. Wulffraat, R. Sorensen, S. Dupuis-Girod, A. Fischer, M. Cavazzana-Calvo, E. G. Davies, W. Kuis, W. H. K. Lundlaan, and L. Leiva. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. New England Journal of Medicine 346:1185-1193.

Li, Z., J. Dullmann, B. Schiedlmeier, M. Schmidt, C. v. Kalle, J. Meyer, M. Forster, C. Stocking, A. Wahlers, O. Frank, W. Ostertag, K. Kulcke, H.-G. Eckert, B. Fehse, and C. Baum. 2002. Murine leukemia induced by retroviral gene marking. Science 296:497.

9. Myers, L. A., D. D. Patel, J. M. Puck, and R. H. Buckley. 2002. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99:872-878.

Rabbitts, T. H. 1998. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes and Development 12:2651-2657.